CA2855005C - Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions - Google Patents

Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions Download PDF

Info

Publication number
CA2855005C
CA2855005C CA2855005A CA2855005A CA2855005C CA 2855005 C CA2855005 C CA 2855005C CA 2855005 A CA2855005 A CA 2855005A CA 2855005 A CA2855005 A CA 2855005A CA 2855005 C CA2855005 C CA 2855005C
Authority
CA
Canada
Prior art keywords
ylmethyl
tetrahydro
quinoline
skin
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2855005A
Other languages
English (en)
French (fr)
Other versions
CA2855005A1 (en
Inventor
Mohammed I. Dibas
Edward C. HSIA
John E. Donello
Daniel W. Gil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2855005(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CA2855005A1 publication Critical patent/CA2855005A1/en
Application granted granted Critical
Publication of CA2855005C publication Critical patent/CA2855005C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
CA2855005A 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions Active CA2855005C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161558104P 2011-11-10 2011-11-10
US61/558,104 2011-11-10
PCT/US2012/064075 WO2013070861A1 (en) 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Publications (2)

Publication Number Publication Date
CA2855005A1 CA2855005A1 (en) 2013-05-16
CA2855005C true CA2855005C (en) 2016-11-22

Family

ID=47178364

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2855005A Active CA2855005C (en) 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Country Status (22)

Country Link
US (4) US20130123303A1 (cg-RX-API-DMAC7.html)
EP (3) EP2776034B1 (cg-RX-API-DMAC7.html)
JP (2) JP6359456B2 (cg-RX-API-DMAC7.html)
KR (1) KR102004563B1 (cg-RX-API-DMAC7.html)
CN (1) CN104136029A (cg-RX-API-DMAC7.html)
AR (1) AR088845A1 (cg-RX-API-DMAC7.html)
AU (2) AU2012335803B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014011336A2 (cg-RX-API-DMAC7.html)
CA (1) CA2855005C (cg-RX-API-DMAC7.html)
CL (1) CL2014001242A1 (cg-RX-API-DMAC7.html)
DK (1) DK2776034T3 (cg-RX-API-DMAC7.html)
ES (1) ES2635421T3 (cg-RX-API-DMAC7.html)
IL (3) IL232483B (cg-RX-API-DMAC7.html)
MX (1) MX350662B (cg-RX-API-DMAC7.html)
MY (1) MY182553A (cg-RX-API-DMAC7.html)
PH (1) PH12014501051A1 (cg-RX-API-DMAC7.html)
RU (2) RU2630978C2 (cg-RX-API-DMAC7.html)
SG (3) SG11201402246RA (cg-RX-API-DMAC7.html)
TW (3) TWI708604B (cg-RX-API-DMAC7.html)
UA (1) UA109359C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013070861A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201403396B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
ES2765264T3 (es) * 2013-05-06 2020-06-08 Allergan Inc Agonistas alfa-adrenérgicos para el tratamiento de traumatismo tisular
FR3061434B1 (fr) * 2017-01-04 2019-07-12 Pierre Fabre Dermo-Cosmetique Composition cosmetique comprenant une association d'huile de pongamia et de pentylene glycol 4-t-butylcyclohexanol pour lutter contre la rosacee
RU2727695C1 (ru) * 2020-02-13 2020-07-22 Мурад Умарович Магомедов Способ комплексного лечения ринофимы

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1676579T3 (da) * 1998-05-08 2009-03-16 Univ Miami Anvendelse af sub-antimikrobielle tetracykliner til behandling af okulær rosacea
WO2004073708A1 (en) * 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide and brimonidine for treating ocular conditions
US20010049369A1 (en) * 2000-02-10 2001-12-06 Jablonski Monica M. Brimonidine compositions and methods for retinal degeneration
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US20040146539A1 (en) * 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
JP4975440B2 (ja) * 2003-11-20 2012-07-11 オセラ・ホールディング・インコーポレイテッド 黄斑変性およびその他の眼科疾患の改善
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
DK1761266T3 (da) * 2004-05-25 2013-08-05 Galderma Pharma Sa Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme
US20070203144A1 (en) * 2006-01-17 2007-08-30 Allergan, Inc. Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals
US7323477B2 (en) 2006-02-02 2008-01-29 Allergan, Inc. 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
RU2321399C1 (ru) * 2006-06-01 2008-04-10 Федеральное государственное учреждение "Нижегородский научно-исследовательский кожно-венерологический институт Федерального агентства по здравоохранению и социальному развитию" Способ лечения больных розацеа
WO2008124151A2 (en) * 2007-04-09 2008-10-16 Avicena Group, Inc. Use of creatine compounds for the treatment of eye disorders
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
US8455548B2 (en) * 2007-10-18 2013-06-04 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
WO2010014552A1 (en) * 2008-08-01 2010-02-04 Alpha Synergy Development, Inc. Vasoconstriction compositions and methods of use
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
FR2942138A1 (fr) 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
MX2012004890A (es) * 2009-10-26 2012-09-28 Galderma Pharma Sa Metodos para tratar o prevenir eritema agudo.
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
CA2792649A1 (en) * 2010-03-26 2011-09-29 Michael Graeber Improved methods and compositions for safe and effective treatment of telangiectasia
KR20170018974A (ko) * 2010-03-26 2017-02-20 갈데르마 리써어치 앤드 디벨로프먼트 홍반의 유효하고 안전한 치료를 위한 개선된 방법 및 조성물
KR20130128375A (ko) * 2010-08-06 2013-11-26 갈데르마 리서치 & 디벨로프먼트 피부 질환을 치료 또는 예방하기 위한 화합물들의 배합물

Also Published As

Publication number Publication date
TW202014189A (zh) 2020-04-16
WO2013070861A1 (en) 2013-05-16
MY182553A (en) 2021-01-25
KR102004563B1 (ko) 2019-07-26
JP2017149767A (ja) 2017-08-31
RU2630978C2 (ru) 2017-09-15
SG10201609145PA (en) 2016-12-29
TW201713338A (zh) 2017-04-16
CL2014001242A1 (es) 2014-11-14
TW201328694A (zh) 2013-07-16
US20150231128A1 (en) 2015-08-20
JP6359456B2 (ja) 2018-07-18
EP2776034A1 (en) 2014-09-17
ZA201403396B (en) 2015-07-29
AU2012335803B2 (en) 2016-05-26
US20170095466A1 (en) 2017-04-06
DK2776034T3 (en) 2017-07-10
RU2667645C1 (ru) 2018-09-21
US20160051534A1 (en) 2016-02-25
JP2014533271A (ja) 2014-12-11
AU2016216627A1 (en) 2016-09-08
IL232483A0 (en) 2014-06-30
EP3763370A1 (en) 2021-01-13
IL261269A (en) 2018-10-31
AR088845A1 (es) 2014-07-10
MX350662B (es) 2017-09-13
CA2855005A1 (en) 2013-05-16
EP2776034B1 (en) 2017-03-22
NZ624771A (en) 2016-11-25
US20130123303A1 (en) 2013-05-16
EP3184110B1 (en) 2020-10-07
BR112014011336A2 (pt) 2017-05-02
RU2014122758A (ru) 2015-12-20
TWI580424B (zh) 2017-05-01
SG10201809506TA (en) 2018-11-29
MX2014005640A (es) 2014-09-22
SG11201402246RA (en) 2014-06-27
US9308201B2 (en) 2016-04-12
PH12014501051A1 (en) 2022-11-02
KR20140107237A (ko) 2014-09-04
AU2016216627B2 (en) 2017-10-19
AU2012335803A1 (en) 2014-05-29
TWI708604B (zh) 2020-11-01
ES2635421T3 (es) 2017-10-03
JP6526737B2 (ja) 2019-06-05
IL268757A (en) 2019-10-31
EP3184110A1 (en) 2017-06-28
CN104136029A (zh) 2014-11-05
IL232483B (en) 2018-10-31
UA109359C2 (xx) 2015-08-10

Similar Documents

Publication Publication Date Title
AU2016216627B2 (en) Pharmaceutical compositions comprising 7-(1H-Imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
US10201535B2 (en) Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
US20140235685A1 (en) Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
NZ624771B2 (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140508